The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Midazolam (Epistatus®) has been accepted for use in the treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years. This product provides a licensed alternative to unlicensed preparations.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - October 2017|